EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
EyePoint Pharmaceuticals Inc
Other Current Liabilities
EyePoint Pharmaceuticals Inc
Other Current Liabilities Peer Comparison
Competitive Other Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
EyePoint Pharmaceuticals Inc
NASDAQ:EYPT
|
Other Current Liabilities
$39.6m
|
CAGR 3-Years
241%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
63%
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Current Liabilities
$3.3B
|
CAGR 3-Years
21%
|
CAGR 5-Years
17%
|
CAGR 10-Years
14%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Current Liabilities
$6.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
32%
|
CAGR 10-Years
13%
|
|
Pfizer Inc
NYSE:PFE
|
Other Current Liabilities
$24.5B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
8%
|
|
Merck & Co Inc
NYSE:MRK
|
Other Current Liabilities
$5.4B
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
7%
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Current Liabilities
$4.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
See Also
What is EyePoint Pharmaceuticals Inc's Other Current Liabilities?
Other Current Liabilities
39.6m
USD
Based on the financial report for Mar 31, 2024, EyePoint Pharmaceuticals Inc's Other Current Liabilities amounts to 39.6m USD.
What is EyePoint Pharmaceuticals Inc's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
63%
Over the last year, the Other Current Liabilities growth was 2 943%. The average annual Other Current Liabilities growth rates for EyePoint Pharmaceuticals Inc have been 241% over the past three years , and 63% over the past ten years .